These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2461854)

  • 1. A patient with Graves' disease who developed hypothyroidism associated with thyroid stimulation blocking immunoglobulin during anti-thyroid drug therapy.
    Inomata H; Tsuyusaki T; Sasaki N; Tamaru K; Niimi H; Nakajima H
    Endocrinol Jpn; 1988 Jun; 35(3):379-84. PubMed ID: 2461854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mechanism of spontaneous hypothyroidism in patients with Graves' disease after antithyroid drug treatment.
    Tamai H; Hirota Y; Kasagi K; Matsubayashi S; Kuma K; Iida Y; Konishi J; Okimura MC; Walter RM; Kumagai LF
    J Clin Endocrinol Metab; 1987 Apr; 64(4):718-22. PubMed ID: 2434520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of primary hypothyroidism with the appearance of blocking-type antibody to thyrotropin receptor in Graves' disease in late pregnancy.
    Ueta Y; Fukui H; Murakami H; Yamanouchi Y; Yamamoto R; Murao A; Santou Y; Taniguchi S; Mitani Y; Shigemasa C
    Thyroid; 1999 Feb; 9(2):179-82. PubMed ID: 10090319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paired determination of thyroid-stimulating and TSH-binding inhibitory activities in patients with Graves' disease during antithyroid drug treatment.
    Kasagi K; Iida Y; Konishi J; Misaki T; Arai K; Endo K; Torizuka K; Kuma K
    Acta Endocrinol (Copenh); 1986 Apr; 111(4):474-80. PubMed ID: 2422860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of hypothyroidism with thyroid stimulation blocking antibody long after treatment with antithyroid drugs in a patient with hyperthyroid Graves' disease: a case report.
    Kasuga Y; Sugenoya A; Kobayashi S; Shimizu T; Onuma H; Shingu K; Asanuma K; Hama Y; Iida F
    Endocr J; 1993 Apr; 40(2):227-30. PubMed ID: 7524926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease.
    Kashiwai T; Hidaka Y; Takano T; Tatsumi KI; Izumi Y; Shimaoka Y; Tada H; Takeoka K; Amino N
    Endocr J; 2003 Feb; 50(1):45-9. PubMed ID: 12733708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
    Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical studies on abnormal thyroid stimulators in patients with Graves' disease. II. Clinical significance of measuring TSAb and TBII in patients with euthyroid Graves' disease and patients with hyperthyroid Graves' disease during antithyroid drug treatment].
    Uno C; Nishikawa M
    Nihon Naibunpi Gakkai Zasshi; 1988 Mar; 64(3):206-15. PubMed ID: 2456230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Onset of subacute aggravation of chronic thyroiditis followed immediately by transient hypothyroidism during antithyroid drug therapy for Graves' hyperthyroidism.
    Shigemasa C; Shirota K; Urabe K; Kouchi T; Mitani Y; Ueta Y; Yoshida A; Mashiba H
    Horm Res; 1991; 35(5):208-12. PubMed ID: 1687041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease.
    Tamaki H; Amino N; Aozasa M; Mori M; Tanizawa O; Miyai K
    J Clin Endocrinol Metab; 1987 Aug; 65(2):324-30. PubMed ID: 2885336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in thyroid-stimulating and TSH-binding inhibitory activities in a patient who developed hyperthyroidism due to Graves' disease following primary hypothyroidism.
    Kasagi K; Konishi J; Iida Y; Mori T; Torizuka K
    Clin Endocrinol (Oxf); 1986 Nov; 25(5):519-25. PubMed ID: 2887308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of spontaneous hypothyroidism in patients with Graves' disease treated with antithyroidal drugs: clinical, immunological, and histological findings in 26 patients.
    Tamai H; Kasagi K; Takaichi Y; Takamatsu J; Komaki G; Matsubayashi S; Konishi J; Kuma K; Kumagai LF; Nagataki S
    J Clin Endocrinol Metab; 1989 Jul; 69(1):49-53. PubMed ID: 2471711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid-stimulating antibody in a patient with euthyroid Graves' disease.
    Kubo T; Toki J; Kado Y; Kurihara M; Moriwake T; Kanzaki S; Seino Y
    Endocr J; 2000 Apr; 47(2):197-201. PubMed ID: 10943745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two Graves' disease patients who spontaneously developed hypothyroidism after antithyroid drug treatment: characteristics of epitopes for thyrotropin receptor antibodies.
    Chung HK; Kim WB; Park DJ; Kohn LD; Tahara K; Cho BY
    Thyroid; 1999 Apr; 9(4):393-9. PubMed ID: 10319947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs.
    Kawai K; Tamai H; Matsubayashi S; Mukuta T; Morita T; Kubo C; Kuma K
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):551-6. PubMed ID: 8548939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.